Protalix Biotherapeutics Company Insiders

Protalix Biotherapeutics Management Team Effectiveness

The company has Return on Asset of 0.031 % which means that on every $100 spent on assets, it made $0.031 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0764 %, implying that it generated $0.0764 on every 100 dollars invested. Protalix Biotherapeutics' management efficiency ratios could be used to measure how well Protalix Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Protalix Biotherapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.09 in 2025, whereas Return On Equity is likely to drop 0.06 in 2025. At this time, Protalix Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.04 in 2025, whereas Total Assets are likely to drop slightly above 52.1 M in 2025. Common Stock Shares Outstanding is likely to rise to about 85.1 M in 2025, whereas Net Loss is likely to drop (14.1 M) in 2025.

Protalix Biotherapeutics Workforce Comparison

Protalix Biotherapeutics Profit Margins

The company has Net Profit Margin of 0.05 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.4 %, which entails that for every 100 dollars of revenue, it generated $0.4 of operating income.

Protalix Biotherapeutics Insider Trading History

Protalix Biotherapeutics Notable Stakeholders

The success or failure of an entity such as Protalix Biotherapeutics often depends on how effective the management is. Protalix Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Protalix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Protalix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Protalix Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Protalix Biotherapeutics. Check Protalix Biotherapeutics' Beneish M Score to see the likelihood of Protalix Biotherapeutics' management manipulating its earnings.

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.